Abstract: With an unrelenting drive in the biotechnology research area, Creative Biolabs unveils its antiviral drug discovery services to global scientists including HTS services of SARS-CoV-2 drug candidates, broad-spectrum SARS-CoV-2 antiviral drug discovery services, nucleoside analogue inhibitors, etc.
Discovery and development of antiviral medications are of great importance for fighting against new pathogens and old ones. With the ongoing outbreak of COVID-10, scientists have spent considerable efforts and dedication to helping identify antiviral products that could potentially cure, or eradicate SARS-CoV-2.
Equipped with cutting-edge techniques and years of experience in antiviral medication development, Creative Biolabs has rapidly integrated all-round resources and existing research results to develop effective antiviral drugs. The comprehensive services begin with novel drug candidates screening, neutralizing antibody development, inhibitors discovery and follows a well-defined antiviral developmental pathway.
HTS Services of SARS-CoV-2 Drug Candidates
High-throughput screening (HTS) is an automated process used in drug discovery to rapidly identify hits from compound libraries, such as active compounds, inhibitors, proteins, antibodies and peptides.
For antiviral candidates, HTS has shown great potential in broad-spectrum anti-CoV agents discovery covering SARS-CoV and MERS-CoV. And high-throughput screening for SARS-CoV-2 at Creative Biolabs provides a flexible and reliable method for drug discovery with full consideration to compounds library, suitable assays, robotic system and data analysis system.
Broad-spectrum SARS-CoV-2 Antiviral Drug Discovery Services
The broad-spectrum antiviral drug is a kind of agents used to prevent and treat virus infection. By inhibiting virus replication and reproduction in infected cells or improving cellular defence system, these broad-spectrum antiviral drugs are effective in the clinical treatment of viral infection, as well as for SARS-CoV-2 infection.
Creative Biolabs provides comprehensive recombinant SARS-CoV-2 IFN-alpha products and drug development services, which have been demonstrated to be effective in anti-viral activity and immune response improvement. IFN-beta candidate is also available at Creative Biolabs, and it stands a good chance of being a candidate for the treatment of SARS-CoV-2 infections since it has been confirmed to effectively inhibit the replication of SARS virus.
Nucleoside Analogue Inhibitors
As the basic components of RNA and DNA, the development and application of nucleoside drugs mainly focus on antiviral and anti-tumor fields. According to the advantages of nucleoside analogue, Creative Biolabs provides comprehensive R&D services of SARS-CoV-2 nucleoside analogues based on multiple action mechanisms, such as Ribavirin, Remdesivir, NHC, BCX4430, Gemcitabine Hydrochloride, etc.
“Compared to SARS-CoV and MERS-CoV, the new coronavirus seems to be less pathogenic and more transmissible,” said a senior scientist at Creative Biolabs. “Thus effective vaccines and drugs are urgently needed. Through our first-class services, our team hopes to facilitate related researches all over the world.”
More information can be found on https://sars-cov-2.creative-biolabs.com/.
About Creative Biolabs
Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.